26,305 Prestige Consumer Healthcare Inc. $PBH Shares Purchased by Profund Advisors LLC

Key Points

• Profund Advisors increased its Prestige Consumer Healthcare stake by 356.2% in the third quarter, purchasing 26,305 additional shares. Institutional investors and hedge funds collectively own 99.95% of PBH.
• Analyst sentiment is mixed, with one Buy, three Hold, and one Sell rating; the stock carries an overall “Hold” rating and an average price target of $67.67.
• Prestige Consumer Healthcare’s latest quarterly results exceeded expectations, with earnings of $0.98 per share and revenue of $265.71 million, up 6.5% year over year.

Profund Advisors LLC boosted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 356.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,690 shares of the company's stock after buying an additional 26,305 shares during the quarter. Profund Advisors LLC owned 0.07% of Prestige Consumer Healthcare worth $1,545,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in Prestige Consumer Healthcare during the 2nd quarter worth about $30,000. Versant Capital Management Inc grew its position in Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after acquiring an additional 235 shares in the last quarter. Cornerstone Planning Group LLC acquired a new position in Prestige Consumer Healthcare in the 1st quarter valued at about $44,000. Pinnacle Wealth Planning Services Inc. grew its position in Prestige Consumer Healthcare by 69.3% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,153 shares of the company's stock valued at $53,000 after acquiring an additional 472 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Prestige Consumer Healthcare during the second quarter worth about $80,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Zacks Research downgraded shares of Prestige Consumer Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 29th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $67.67.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $49.78 on Tuesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $71.07. The stock has a market cap of $2.36 billion, a PE ratio of 10.81, a price-to-earnings-growth ratio of 1.50 and a beta of 0.34. The firm has a fifty day moving average price of $48.51 and a 200 day moving average price of $54.12.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The company had revenue of $265.71 million during the quarter, compared to analysts' expectations of $253.02 million. During the same quarter in the previous year, the business earned $0.90 earnings per share. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.